Discover how in silico techniques combined with traditional medicinal chemistry approaches are applied in a structure-based drug discovery program
See how the team overcame challenges of obtaining sufficient permeability for oral bioavailability and sufficient potency and selectivity over related targets using molecular modeling methods
Learn how QM-based pKa prediction and Free Energy Perturbation (FEP+) were used to prioritize compounds and drive programs forward efficiently
Ask questions to gain further insight from the speaker to apply to your work
In Silico Driven Drug Discovery of a Zwitterionic Integrin αvβ6 Development Candidate for Fibrosis
January 31, 2023
11:00 AM ET / 8:00 AM PT / 4:00 PM GMT
CONVERSATION SERIES: Stories of Drug Hunting In A Digital Age
We are excited to bring you Stories of Drug Hunting in a Digital Age – a series of conversations with veteran drug hunters who will share their unique drug discovery stories, from idea to development candidate. You’ll hear about the teams and tools used to progress programs and have an opportunity to ask questions.
In this inaugural webinar of the series, Bryce A. Harrison from Morphic Therapeutic, will share the story of the discovery of MORP-627, an αvβ6 inhibitor development candidate for fibrotic disease.
About the event
Overview
Bryce A. Harrison is a medicinal chemist and project leader with 18 years of experience in the biotech sector, including his current role as Director in the chemistry group at Morphic Therapeutic. During this conversation, he will share how his team investigated a series of zwitterionic alpha amino acid αvβ6 inhibitors in a structurally enabled program using a variety of in silico techniques combined with traditional medicinal chemistry approaches – which led to the discovery of MORF-627, a highly potent and selective αvβ6 inhibitor development candidate.
Highlights